Abstract
Considerable efforts have been invested to improve local control of the glioma disease although its infiltrative nature leading to whole brain involvement is a fundamental characteristic and antagonistic to this endeavour. The typically local recurrence of glioblastoma in about 80% of the cases has prompted intracavitary treatments of which presently only a biodegradable wafer containing carmustine has shown statistically significant benefit regarding survival in three phase III trials.
Keywords
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Brem H, Mahaley MS, Vick NA, Black KL, Schold SC, Burger PC, Friedman AH, Ciric IS, Eller TW, Cozzens JW (1991) Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomas. J Neurosurg 74: 441–446
Brem H, Tamargo RJ, Olivi A, Pinn M, Weingart JD, Wharam M, Epstein JI (1994) Biodegradable polymers for controlled delivery of chemotherapy with and without radiation therapy in the monkey brain. J Neurosurg 80: 283–290
Brem H, Piantadosi S, Burger PC, Walker M, Selker R, Vick NA, Black K, Sisti M, Brem S, Mohr G, Morawetz R, Schold SC (1995) Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. Lancet 345: 1008–1012
Broggi G, Franzini A (1996) Bleomycin for cystic craniopharyngioma. J Neurosurg 84: 1080–1081
Dalbasti T, Oktar N, Cagli S, Ozdamar N (2002) Local interstitial chemotherapy with sustained release bucladesine in de novo glioblastoma multiforme: a preliminary study. J Neurooncol 56: 167–174
DiMecco F, Li KW, Tyler BM, Wolf AS, Brem H, Olivi A (2002) Local delivery of mitoxantrone for the treatment of malignant brain tumors in rats. J Neurosurg 97: 11783–1178
Emerich DF, Winn SR, Bartus RT (2002) Injection of chemotherapeutic microspheres and glioma. Eradicating tumors in rats. Cell Transplant 11: 47–54
Fleming AB, Saltzman WM (2002) Pharmacokinetics of the carmustine implant. Clin Pharmacokinet 41: 403–419
Giese A, Bjerkvig R, Berens M, Westphal M (2003) The cost of migration. J Clin Oncol (in press)
Hanes J, Sills A, Zhao Z, Suh KW, Typer B, DiMeco F, Brat DJ, Chot MA, Leong KW, Pardoll DM, Brem H (2001) Controlled local delivery of interleukin-2 by biodegradable polymers protects animals from experimental brain tumors and liver tumors. Pharm Res 18: 899–906
Hayes RL, Koslow M, Hiesiger EM, Hymes KB, Hochster HS, Moore EJ, Pierz DM, Chen DK, Budzilovich GN, Ransohoff J (1995) Improved long-term survival after intracavitary interleukin-2 and lymphokine activated killer cells for adults with recurrent malignant glioma. Cancer 76: 840–852
Hassenbusch SJ, Levin VA, Cozzens J, Paleologos N, Vick N, Smith D, Phuphanich S, Brem S, Chen T, Chamberlain M, Hariharan S, Pietronigro D (2002) Multi-center phase I/II trial of stereotactic injection of DTI-015 into inoperable recurrent malignant gliomas. Neurooncology 4: 370 (abstract)
Joki T, Machluf M, Atala A, Zhu J, Seyfried NT, Dunn IF, Abe T, Carroll RS, Black PM (2001) Continuous release of endostatin from microencapsulated engineered cells for tumor therapy. Nat Biotech 1: 35–39
Kelly PJ, Hunt C (1994) The limited value of cytoreductive surgery in elderly patients with malignant gliomas. Neurosurgery 34: 62–67
Köppen JA, Herrmann HD, Giese A, Franz HR, Raschdorff C, von Koschitzky H, Westphal M (1991) Lymphokine-activated killer cells, interleukin-2 and tumor necrosis factor in a malignant glioma: clinical and laboratory findings. Reg Cancer Treatm 3: 338–344
Lacroix M, Abi-said D, Founey DR (2001) A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg 95: 190–198
Loo TL, Dion RL, Dixon RL, Rall DP (1966) The anti-tumor agent 1,3-bis(2-chloroethyl)-1-nitrosourea. J Pharm Sci 55: 492–497
Mariani L, Beaudry C, McDonough WS, Hoelzinger DB, Demuth T, Ross KR, Berens T, Coons SW, Watts G, Trent JM, Wei JS, Giese A, Berens ME (2001) Glioma cell motility is associated with reduced ranscription of proapoptotic and proliferation genes: a cDNA microarray analysis. J Neurooncol 53: 161–176
Menei P, Venier MC, Gameli E, Saint-Andre JP, Hayek G, Jadaud E, Fournier D, Mercier P, Guy G, Benoit JP (1999) Local and sustained delivery of 5-fluoruracil from biodegradable microspheres for the radiosensitization of glioblastoma: a pilot study Cancer 86: 325–330
Nakagawa H, Maeda N, Tsuzuki T, Suzuki T, Hirayama A, Miyahara E, Wada K (2001) Intracavitary chemotherapy with 5-fluoro-2-deoxyuridine (FdUrd) in malignant brain tumors. Jpn J Clin Oncol 31: 251–258
Prados MD, Levin V (2000) Biology and treatment of malignant glioma. Semin Oncol 27 [Suppl] 6: 1–10
Prados MD, Schold SC, Fine HA, Jaeckle K, Hochberg F, Mechtler L, Fetell MR, Phuphanich S, Feun L, Janus TJ, Ford K, Graney W (2003) A randomized, double blind, placebo controlled, phase 2 study of RMP-7 in combination with carbopla-tin administered intravenously for the treatment of recurrent malignant glioma. Neurooncology 5: 96–103
Read TA, Sorensen DR, Mahesparan R, Enger PO, Timpl R, Olsen BR, Hjelstuen MH, Haraldseth O, Bjerkvig R (2001) Local endostatin treatment of gliomas administered by micro-encapsulated producer cells. Nat Biotech 1: 29–34
Rhines LD, Sampath P, Dolan ME, Tyler H, Brem H, Weingart J (2000) 06-benzylguanine potentiates the anti-tumor effect of locally delivered carmustine against an intracranial rat glioma. Cancer Res 60: 6307–6310
Salcman M (1994) The value of cytoreductive surgery. Clin Neurosurg 41: 464–488
Seong H, An TK, Khang G, Choi SU, Lee CO, Lee HB (2003) BCNU-loaded poly(D,L-lactide-co-glycolide) wafer and antitumor activity against XF-498 human CNS tumor cells in vitro. Int J Pharm 251: 1–12
Stewart LA (2002) Chemotherapy in adult high grade glioma: A systematic review and meta-analysis of individual patient data from 12 randomized trials. Lancet 359: 1011–1018
Storm PB, Moriarty JL, Tyler B, Burger PC, Brem H, Weingart J (2002) Polymer delivery of comptothecin against 9L gliosarcoma: release, distribution and efficacy. J Neurooncol 56: 209–217
Stummer W, Novotny A, Stepp H, Goetz C, Bise K, Reulen HJ (2000) Fluorescence-guided resection of glioblastoma multiforme utilizing 5-ALA-induced porphyrins. A prospective study in 52 consecutive patients. J Neurosurg 93: 1003–1013
Valtonen S, Timonen U, Toivanen P, Kalimo H, Kivipelto L, Heiskanen O, Unsgaard G, Kuurne T (1997) Interstitial chemotherapy with carmustine-loaded polymers for high grade gliomas: a randomized double blind study. Neurosurgery 41: 44–49
Voges J, Sturm V, Lehrke R, Treuer H, Gauss C, Berthold F (1997) Cystic craniopharyngioma: Long-term results after intracavitary irradiation with stereotactically applied colloidal Remitting radioactive sources. Neurosurgery 40: 263–270
Wang PP, Frazier J, Brem H (2002) Local drug delivery to the brain. Adv Drug Del Rev 54: 987–1013
Weller M, Rieger J, Grimmel C, Van Meir EG, de Tribolet N, Krajewski S, Reed JC, von Deimling A, Dichgans J (1998) Predicting chemoresistance in human malignant glioma cells: the role of molecular genetic analyses. Int J Cancer 79: 640–644
Westphal M, Hilt DC, Bortey E, Delavault P, Olivares R, Warnke P, Whittle IR, Jääskeläinen J, Ram Z (2003) A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neurooncology 5: 6–15
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2003 Springer-Verlag/Wien
About this paper
Cite this paper
Westphal, M., Lamszusand, K., Hilt, D. (2003). Intracavitary Chemotherapy for Glioblastoma: Present Status and Future Directions. In: Westphal, M., Tonn, JC., Ram, Z. (eds) Local Therapies for Glioma Present Status and Future Developments. Acta Neurochirurgica Supplements, vol 88. Springer, Vienna. https://doi.org/10.1007/978-3-7091-6090-9_11
Download citation
DOI: https://doi.org/10.1007/978-3-7091-6090-9_11
Publisher Name: Springer, Vienna
Print ISBN: 978-3-211-40355-6
Online ISBN: 978-3-7091-6090-9
eBook Packages: Springer Book Archive